[go: up one dir, main page]

WO2020117151A3 - A combination comprising fingolimod and modafinil - Google Patents

A combination comprising fingolimod and modafinil Download PDF

Info

Publication number
WO2020117151A3
WO2020117151A3 PCT/TR2019/050480 TR2019050480W WO2020117151A3 WO 2020117151 A3 WO2020117151 A3 WO 2020117151A3 TR 2019050480 W TR2019050480 W TR 2019050480W WO 2020117151 A3 WO2020117151 A3 WO 2020117151A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
modafinil
combination
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050480
Other languages
French (fr)
Other versions
WO2020117151A2 (en
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority to EP19892411.0A priority Critical patent/EP3810112A4/en
Publication of WO2020117151A2 publication Critical patent/WO2020117151A2/en
Publication of WO2020117151A3 publication Critical patent/WO2020117151A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising fingolimod or a pharmaceutically acceptable salt thereof and modafinil or a pharmaceutically acceptable salt thereof for use in the treatment of multiple sclerosis in human, preferably in the prevention or the treatment of fatigue symptom of multiple sclerosis disease.
PCT/TR2019/050480 2018-06-21 2019-06-20 A combination comprising fingolimod and modafinil Ceased WO2020117151A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19892411.0A EP3810112A4 (en) 2018-06-21 2019-06-20 COMBINATION CONTAINING FINGOLIMOD AND MODAFINIL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808821 2018-06-21
TR2018/08821 2018-06-21

Publications (2)

Publication Number Publication Date
WO2020117151A2 WO2020117151A2 (en) 2020-06-11
WO2020117151A3 true WO2020117151A3 (en) 2020-08-27

Family

ID=70975010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050480 Ceased WO2020117151A2 (en) 2018-06-21 2019-06-20 A combination comprising fingolimod and modafinil

Country Status (2)

Country Link
EP (1) EP3810112A4 (en)
WO (1) WO2020117151A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178062A1 (en) * 2007-03-01 2011-07-21 Allison Brett D Indole and benzothiophene compounds as modulators of the histamine h3 receptor
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
US20170020885A1 (en) * 2015-07-22 2017-01-26 John Hsu Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417165D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178062A1 (en) * 2007-03-01 2011-07-21 Allison Brett D Indole and benzothiophene compounds as modulators of the histamine h3 receptor
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
US20170020885A1 (en) * 2015-07-22 2017-01-26 John Hsu Composition Comprising a Therapeutic Agent and a Respiratory Stimulant and Methods for the Use Thereof
WO2018082814A1 (en) * 2016-11-07 2018-05-11 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SANFORD, M.: "Fingolimod: a review of its use in relapsing-remitting multiple sclerosis", DRUGS, vol. 74, no. 12, 26 July 2014 (2014-07-26), pages 1411 - 1433, XP055763237 *

Also Published As

Publication number Publication date
WO2020117151A2 (en) 2020-06-11
EP3810112A4 (en) 2022-03-16
EP3810112A2 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
CY1124432T1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF N-(3,5-DIMETHODIPHENYL)-N'-(1-METHYLATHYL)-N-[3-(1--METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANO- 1,2-DIAMINE
MX2021002321A (en) Novel methods.
MX2021004431A (en) Novel processes.
MX383665B (en) COMPOSITIONS OF DONEPEZIL AND METHODS FOR TREATING ALZHEIMER'S DISEASE.
EP4596041A3 (en) Farnesoid x receptor agonists and uses thereof
EP4424328A3 (en) Treatment of hidradenitis suppurativa using jak inhibitors
EP4467195A3 (en) Therapeutic agents for neurodegenerative diseases
EP4335418A3 (en) Compositions and methods for treating pterygium
EP4275750A3 (en) Treatment of alzheimer's disease in a particular patient population
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
EP4548974A3 (en) Somatostatin modulators and uses thereof
ZA202201827B (en) Therapeutic fusion proteins
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
MX2019015280A (en) Statin compositions and methods for use in treating synucleinopathies.
CA3154083A1 (en) Methods of promoting scfa production by gut microbiota
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
WO2020117151A3 (en) A combination comprising fingolimod and modafinil
WO2019245513A3 (en) A combination comprising fingolimod and amantadine
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2018151562A3 (en) Novel benzimidazole derivative having jnk inhibitory activity and use thereof
WO2016130518A3 (en) Methods and compositions for treating muscle disease and disorders
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability
WO2019151964A3 (en) Orally disintegrating formulations of saxagliptin
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19892411

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019892411

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019892411

Country of ref document: EP

Effective date: 20210121

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19892411

Country of ref document: EP

Kind code of ref document: A2